SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy.

Marie-Lucie RacuDana BernardiAniss ChaoucheEgor Zindy Julie NavezPatrizia LoiCalliope MarisJean ClossetJean-Luc Van LaethemChristine DecaesteckerIsabelle SalmonNicky D'Haene

Published in: Cancers (2023)

This study highlights the potential prognostic and predictive role of SMAD4 status in PDAC patients receiving FOLFIRINOX-based NAT.

Keyphrases

locally advanced
epithelial mesenchymal transition
rectal cancer
transforming growth factor
squamous cell carcinoma
lymph node
stem cells
adipose tissue
metabolic syndrome
insulin resistance
bone marrow
glycemic control